Back in March, when we first wrote about migraine drug development, there were no approved therapies addressing the underlying mechanisms of these painful, sometimes chronic, headaches — the most prevalent neurological disorder worldwide. Now, three such drugs have reached the market. The three drugs — Aimovig (erenumab) from Amgen/Novartis, Ajovy (fremanezumab) from Teva Pharmaceuticals,...
Migraine is the most prevalent neurological disorder worldwide. It causes not only painful headaches, but can also be associated with nausea, vomiting, light and noise sensitivity, and fatigue. A migraine attack can last from a few hours to several days. And while 90% of those who suffer from migraines experience them fewer than 15 days...